1. United States v. E.R. Squibb & Sons (1980s antitrust–orphan drug context)

Facts:

• Pharmaceutical company was accused of using market exclusivity and licensing restrictions to block competitors from producing essential drugs for rare conditions.
• This indirectly affected availability and affordability of life-saving medicines (early orphan drug-type drugs).

Issue:

Whether restricting production of essential drugs violates antitrust principles when patient access is affected.

Judgment:

• Courts emphasized that monopoly conduct in essential medicines can be scrutinized under competition law.
• However, enforcement was limited due to regulatory framework.

Legal Principle:

• Even in regulated pharmaceutical markets, anti-competitive conduct affecting drug access can be challenged.

Relevance:

This case influenced later orphan drug debates about balancing exclusivity incentives with public access.

2. United States v. Actavis (2013, Supreme Court of USA)

Facts:

• Although not purely orphan drug-specific, it involved “pay-for-delay” agreements where brand-name drug companies paid generic manufacturers to delay entry.
• This affected access to high-cost specialty medicines, including rare disease treatments.

Issue:

Whether such settlement agreements violate antitrust laws.

Judgment:

• Supreme Court ruled that pay-for-delay agreements can be illegal under antitrust law.

Legal Principle:

• Even if a settlement exists, courts will examine whether it unreasonably restricts competition and increases drug prices.

Relevance to orphan drugs:

• Many orphan drugs rely on exclusivity; delaying generics directly impacts rare disease patients’ access.

3. Novartis AG v. Union of India (2013, India Supreme Court)

Facts:

• Company sought patent protection for Imatinib Mesylate (cancer drug used in rare conditions too).
• India rejected patent under Section 3(d) of the Patent Act (no “enhanced efficacy”).
• Patient groups argued that granting patent would make the drug unaffordable.

Issue:

Whether evergreening patents should be allowed when they restrict access to essential medicines.

Judgment:

• Supreme Court rejected patent.
• Confirmed strict standards for pharmaceutical patents.

Legal Principle:

• Public access to medicines outweighs minor modifications without therapeutic improvement.

Relevance:

This is one of the most important cases globally for orphan drug access:

• Prevents monopoly extension
• Ensures affordable access to critical treatments

4. Association for Molecular Pathology v. Myriad Genetics (2013, USA Supreme Court)

Facts:

• Company patented isolated human genes related to breast cancer risk (BRCA1/BRCA2 testing).
• This limited access to genetic testing needed for rare disease diagnosis.

Issue:

Whether human genes can be patented, restricting diagnostic access.

Judgment:

• Court ruled:
  • Naturally occurring DNA cannot be patented
  • Synthetic DNA (cDNA) may be patentable

Legal Principle:

• Natural biological information cannot be monopolized.

Relevance to orphan drugs:

• Genetic tests are critical for rare disease diagnosis
• Prevents monopolies that could restrict diagnostic access and delay treatment

5. R (on the application of) Chandler v. Secretary of State for Health (UK litigation context)

Facts:

• Patient with a rare condition sought access to unapproved or high-cost treatment not routinely available under NHS funding rules.
• Government refusal led to judicial review.

Issue:

Whether denial of expensive orphan treatment violates the right to life and health care obligations.

Judgment:

• Courts generally held that:
  • Governments have discretion in allocating healthcare resources
  • But decisions must be rational, fair, and non-arbitrary

Legal Principle:

• Public health authorities must balance:
  • Cost-effectiveness
  • Clinical need
  • Equity in healthcare distribution

Relevance:

Shows how courts handle rationing of orphan drugs in public systems.

6. Puttaswamy v. Union of India (2017, India Supreme Court – indirectly relevant)

Facts:

• Concerned right to privacy, but extended to bodily autonomy and health data.

Issue relevance:

Used in later healthcare disputes involving:

• Access to genetic therapies
• Rare disease registries
• Experimental orphan drug treatments

Judgment:

• Recognized right to privacy as a fundamental right under Article 21 (right to life).

Legal Principle:

• Health decisions, including access to treatment, are part of personal liberty and dignity.

Relevance to orphan drugs:

Strengthens argument that denial of life-saving orphan drugs may violate constitutional rights.

7. Hoffmann-La Roche Ltd v. Empagran S.A. (2004, USA Supreme Court – global pharma pricing relevance)

Facts:

• Case involved global price fixing of vitamins.
• Though not orphan drugs directly, it affected pharmaceutical pricing behavior worldwide.

Issue:

Whether US antitrust law applies to foreign purchasers harmed by price-fixing.

Judgment:

• Limited extraterritorial application of US antitrust law.

Legal Principle:

• Courts must consider international comity and jurisdiction limits in drug pricing disputes.

Relevance:

Important for orphan drugs because:

• Pricing is global
• Access disputes often cross borders

8. National Pharmaceutical Pricing Authority (NPPA) decisions – Indian tribunal jurisprudence

Facts:

• Government capped prices of essential and some orphan-like drugs.
• Pharma companies challenged price control mechanisms.

Issue:

Whether price control violates trade rights of pharmaceutical companies.

Outcome (various tribunal rulings upheld NPPA powers):

• Courts supported government regulation in public interest.

Legal Principle:

• Drug pricing can be regulated when public health is at stake

Relevance:

Directly impacts orphan drug affordability in India.

CORE LEGAL THEMES IN ORPHAN DRUG ACCESS DISPUTES

Across all these cases, courts focus on:

1. Right to Life vs Market Exclusivity

• Patients argue: life-saving access is fundamental
• Companies argue: innovation requires exclusivity

2. Affordability and Price Regulation

• Courts often support government intervention in extreme pricing cases

3. Patent Law Limitations

• Preventing “evergreening” and unjustified monopolies

4. Competition Law Enforcement

• Blocking anti-competitive practices that restrict availability

5. Constitutional Health Rights

• Especially strong in India and parts of Europe

SIMPLE SUMMARY

Orphan drug litigation is about who controls life-saving medicines for rare diseases:

• Pharma companies → protect innovation and profit
• Patients → demand access and affordability
• Governments → balance cost, access, and sustainability
• Courts → ensure fairness, reasonableness, and protection of life